NDC properties for "Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream" (RxCUI 728126)
About this data
The tables show NDC propoerties for Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream with the RxCUI 728126
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream (RxCUI 728126)
MMSL_CODE | BD28131 |
---|---|
NDA | NDA021717 |
RxCUI | 728126 |
SPL_SET_ID | 4ccdf61b-3128-4a97-a89c-a11e40823938 |
SPL_SET_ID | 8a1b2553-ce65-4557-b33d-cb3dd2a307fa |
SPL_SET_ID | 9838a8a2-dd5a-4eb2-beee-2fb45d35f6de |
Prescribable Synonym | Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream |
RXNAV_STR | Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream |
RxNorm Name | lidocaine 70 MG/ML / tetracaine 70 MG/ML Topical Cream [Pliaglis] |
RxNorm Synonym | Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream |
Related queries | Interactions (for RxCUI 728126) |
NDC Properties
NDC Item 00299610010
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-10 |
NDC Item | 00299610010 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-35 |
NDC Item | 00299610035 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
NDC 9 | 51672-5305 |
---|---|
NDC 10 | 51672-5305-2 |
NDC Item | 51672530502 |
Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
FDA SPL set id | 540569 |
Labeler | Taro Pharmaceuticals U.S.A., Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2018-12-11 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-02 |
NDC Item | 73575000902 |
Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-04 |
NDC Item | 73575000904 |
Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-09 |
NDC Item | 73575000909 |
Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-10 |
NDC Item | 00299610010 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-35 |
NDC Item | 00299610035 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
NDC 9 | 51672-5305 |
---|---|
NDC 10 | 51672-5305-2 |
NDC Item | 51672530502 |
Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
FDA SPL set id | 540569 |
Labeler | Taro Pharmaceuticals U.S.A., Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2018-12-11 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-02 |
NDC Item | 73575000902 |
Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-04 |
NDC Item | 73575000904 |
Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-09 |
NDC Item | 73575000909 |
Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-10 |
NDC Item | 00299610010 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-35 |
NDC Item | 00299610035 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
NDC 9 | 51672-5305 |
---|---|
NDC 10 | 51672-5305-2 |
NDC Item | 51672530502 |
Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
FDA SPL set id | 540569 |
Labeler | Taro Pharmaceuticals U.S.A., Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2018-12-11 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-02 |
NDC Item | 73575000902 |
Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-04 |
NDC Item | 73575000904 |
Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-09 |
NDC Item | 73575000909 |
Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-10 |
NDC Item | 00299610010 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-35 |
NDC Item | 00299610035 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
NDC 9 | 51672-5305 |
---|---|
NDC 10 | 51672-5305-2 |
NDC Item | 51672530502 |
Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
FDA SPL set id | 540569 |
Labeler | Taro Pharmaceuticals U.S.A., Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2018-12-11 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-02 |
NDC Item | 73575000902 |
Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-04 |
NDC Item | 73575000904 |
Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-09 |
NDC Item | 73575000909 |
Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-10 |
NDC Item | 00299610010 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-35 |
NDC Item | 00299610035 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
NDC 9 | 51672-5305 |
---|---|
NDC 10 | 51672-5305-2 |
NDC Item | 51672530502 |
Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
FDA SPL set id | 540569 |
Labeler | Taro Pharmaceuticals U.S.A., Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2018-12-11 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-02 |
NDC Item | 73575000902 |
Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-04 |
NDC Item | 73575000904 |
Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-09 |
NDC Item | 73575000909 |
Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-10 |
NDC Item | 00299610010 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
NDC 9 | 0299-6100 |
---|---|
NDC 10 | 0299-6100-35 |
NDC Item | 00299610035 |
Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
FDA SPL set id | 127914 |
Labeler | Galderma Laboratories, L.P. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time high | 2017-05-03 |
Marketing effective time low | 2006-06-29 |
Marketing status | COMPLETED |
NDA | NDA021717 |
Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
NDC 9 | 51672-5305 |
---|---|
NDC 10 | 51672-5305-2 |
NDC Item | 51672530502 |
Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
FDA SPL set id | 540569 |
Labeler | Taro Pharmaceuticals U.S.A., Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2018-12-11 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-02 |
NDC Item | 73575000902 |
Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-04 |
NDC Item | 73575000904 |
Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
NDC 9 | 73575-009 |
---|---|
NDC 10 | 73575-009-09 |
NDC Item | 73575000909 |
Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
FDA SPL set id | 500476 |
Labeler | Oba Pharmaceuticals, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2020-01-24 |
Marketing status | ACTIVE |
NDA | NDA021717 |
Related queries | Properties for NDC 9 73575-009 |